Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

DNB Carnegie Access: Spago Nanomedical: Intervju - Positiv utveckling för Tumorad

Spago Nanomedical

Vi intervjuar vd Mats Hansen med anledning av den senaste rekommendationen från DMC att gå vidare med högre doser. Dessutom diskuterar vi de lovande SPECT-bilderna som visar tumörupptag av Tumorad samt nästa steg i utvecklingen.

Hitta intervjun på DNB Carnegie Play: https://youtu.be/7lBi5r0m3EY?si=rnmn9yPz7Kjr2zg4
Detta är uppdragsanalys från DNB Carnegie. Läs mer här: https://www.carnegie.se/en/commissioned-research/

Information
This is a press release from DNB Carnegie. For information about DNB Carnegie commissioned research, see https://www.carnegie.se/en/commissioned-research/, or contact our commissioned research team at cr@carnegie.se.

About Us
DNB Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. DNB Carnegie operates in six countries and has more than 800 employees.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.